Lv1
89 积分 2021-08-20 加入
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
1个月前
已完结
Intra-arterial locoregional therapies for intrahepatic cholangiocarcinoma
1个月前
已完结
CBFβ promotes colorectal cancer progression through transcriptionally activating OPN, FAM129A, and UPP1 in a RUNX2-dependent manner
1个月前
已完结
Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting
2个月前
已完结
Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study
2个月前
已完结
Combination locoregional and systemic therapies in hepatocellular carcinoma
3个月前
已完结
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
4个月前
已完结
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study
4个月前
已完结
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
5个月前
已完结
皖公网安备34019202002308
